PRDX1 Gene Expression and EGFR Pathway Data for Clear Cell Renal Cell Carcinoma

A 997.3 KB supplementary document by Zhi Liang, last updated April 17, 2026, details research on peroxiredoxin 1 (PRDX1) as a therapeutic target in clear cell renal cell carcinoma. The study analyzes 90 pairs of patient samples and integrates data from The Cancer Genome Atlas and Gene Expression Omnibus databases. It describes bioinformatics methods, cell line experiments, and a xenograft mouse model to investigate PRDX1's role in modulating EGFR-dependent AKT pathway activation.

Use Cases

• Validate prognostic biomarkers for clear cell renal cell carcinoma based on PRDX1 expression patterns.
• Study the molecular interaction between PRDX1 and the EGFR juxta-membrane domain described in the co-immunoprecipitation assays.
• Investigate the effects of PRDX1 inhibition on cancer cell proliferation and migration using the described ACHN and 786-O cell line models.
• Analyze the relationship between gene expression profiles and clinical stage in renal cell carcinoma as referenced in the patient sample analysis.

Strengths

• Analysis is based on 90 pairs of clear cell renal cell carcinoma patient samples.
• Integrates data from two major public repositories: The Cancer Genome Atlas and Gene Expression Omnibus.
• Includes validation through in vitro cell line assays and an in vivo xenograft mouse model.

Limitations

• The primary data file is a 997.3 KB DOCX document, which is a small, text-based supplementary file rather than a primary dataset.
• Row count and column-level documentation for any underlying data are unknown.
• Data freshness should be verified, as the last update is listed as a future date (2026-04-17).

Provenance

Source

figshare

Collection Method

Patient microarray analysis combined with public database mining, cell culture assays, and animal modeling as described in the document.

Freshness

Last updated 2026-04-17 05:09:37.